Use of metabolic imaging in managing breast cancer patients
|Download the pocket guide and grid|
18F FDG PET/CT
Fletcher JW. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008 Mar; 49(3):480-508.
Even-Sapir, Einat. Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities. J Nucl Med 2005; 46:1356–1367.
Palomar Munoz A. Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence. Rev Esp Med Nucl. 2010 May-Jun: 29(3):100-8. Epub 2010 Apr 13.
Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Aukema TS, Straver ME, Peeter MJ, Gilhuijs KG, Vogel WV, Rutgers EJ, Olmos RA. Eur J Cancer. 2010 Aug 16.
NEW! - 80 year old female with breast cancer, case study courtesy of Dr Kipper
NEW! - 44-year-old female, with breast cancer, case study courtesy of Dr Michael Kipper, UCSD
NEW! – 63 year old female with breast cancer, Zwanger and Pesiri in Long Island
Kuerer HM, Newman LA. Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Developments and Resolving Controversies. J of Clinical Oncology March 2010.
Hung JC. Filtered Technetium-99m-Sulfur Colloid Evaluated for Lymphoscintigraphy JNM Oct 1995.
Reintgen D. The Role of Lymphoscintigraphy in Lymphatic Mapping for Melanoma and Breast Cancers. JNM Dec 1998.
Results of a Multicenter Patient Registry to Determine the Clinical Impact of Breast-Specific Gamma Imaging, a Molecular Breast Imaging Technique. Weigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA. AJR January 2012.
Breast-Specific Gamma Imaging with 99mTc-Sestamibi and Magnetic Resonance Imaging in the Diagnosis of Breast Cancer – A Comparative Study. Brem RF, Petrovich I, Rapelyea JA, Young H, Teal C, Kelly T. The Breast Journal, Volume 13 Number 5, 2007 465–469.
Positron Emission Mammography (PEM)
Berg WA, Madsen KS, Schilling K, et al. Breast cancer: Comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology. 2011;258(1):59-72.
Schilling K, Franc BL, Kalinyak JE. Pre-surgical detection of malignancies in the contralateral breast using positron emission mammography: Comparisons with magnetic resonance imaging. Presented at: National Consortium of Breast Centers 21st Annual National Interdisciplinary Breast Center Conference; March 2011; Las Vegas, Nev.
New Technologies for Human Cancer Imaging. Frangioni JV. JCO August 20, 2008.
NEW! – breast cancer – PEM case study
18F NaF PET/CT
Grant, Frederick D, et al. Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer. J Nucl Med 2008; 49:68–78.
Bridges, Robert L, et al. An Introduction to Na18F Bone Scintigraphy: Basic Principles, Advanced Imaging Concepts, and Case Examples. J Nucl Med Technol 2007; 35:64–76.
Even-Sapir, Einat, et al. Assessment of Malignant Skeletal Disease: Initial Experience with 18F-Fluoride PET/CT and Comparison Between 18F-Fluoride PET and 18F-Fluoride PET/CT.J Nucl Med 2004; 45:272–278.
Schirrmeister, Holger, et al. Prospective Evaluation of the Clinical Value of Planar Bone Scans, SPECT, and 18F-Labeled NaF PET in Newly Diagnosed Lung Cancer. J Nucl Med 2001; 42:1800–1804.
NEW! – Dr Sheth – breast cancer NaF case study courtesy of Dr Sindu Sheth
Nuclear Medicine Bone Scan
Schirrmeister, Holger, et al. Sensitivity in Detecting Osseous Lesions Depends on Anatomic Localization: Planar Bone Scintigraphy Versus 18FPET. J NucI Med1999; 40:1623-1629.
Lee, Jean H, et al. The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging. J Nucl Med 2009; 50:569–581.
Multi-Gated Acquisition (MUGA)
Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity. deGeus-Oei LF, Mavinkurye-Groothuis AMC, Bellersen L, Gotthardt M, Oyen WJG, Kapusta L, van Laarhoven HWM. J Nucl Med 2011.
Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison with Two-Dimensional Echocardiography, Multiple-Gated Acquisition Scans, and Cardiac Magnetic Resonance Imaging. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, Summers AR, Singal PK, Barac I, Kirkpatrick ID, Jassal DS. JCO Jul 20, 2010.
Palliative Bone Therapy
Serafini, AN, Houston SF, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a dpib;e – blind placebo-controlled clinical trial. J Clin Oncol. 1998; 16:1574-1581.
Sartor O. Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium SM-153 lexidronam to patients with metastic bone pain. Cancer. 2006; Dec 13: [Epub ahead of print].